Caixin
Jan 16, 2023 08:14 PM
CHINA

China Runs Short of Anti-Immune Deficiency Drug as Covid Panic Buying Clears Shelves

Medical staff attend to a patient in the respiratory intensive care unit of a hospital in Huzhou, Zhejiang province, on the evening of Jan. 11. Photo: VCG
Medical staff attend to a patient in the respiratory intensive care unit of a hospital in Huzhou, Zhejiang province, on the evening of Jan. 11. Photo: VCG

A surge in severe Covid cases across China has led to panic buying of an antibody-based medication used to ward off infection, Intravenous Immunoglobulin (IVIG), causing supplies to tighten and prices to skyrocket, patients and medical sources told Caixin.

There was already a nationwide shortage of IVIG at the end of last year, said Zheng Yin, a patient with an inherited immune disorder, and the problem has continued to worsen this month, with the price per dose now as high as 5,000 yuan ($746), compared with an average of 800 yuan in late December.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code
NEWSLETTERS
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription
PODCAST
Caixin Biz Roundup: China’s Door Will Only Open Wider, Liu He Tells Davos
00:00
00:00/00:00